Departamento académico
(FM) Inmunología
Publicaciones (21) Publicaciones en las que ha participado algún/a investigador/a
2024
-
Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma
Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096
-
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials
Nature Communications, Vol. 15, Núm. 1
-
Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010–19: an analysis of data from a consortium of prospective cohort studies
The Lancet HIV, Vol. 11, Núm. 2, pp. e106-e116
-
Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross-priming
Immunological Reviews, Vol. 321, Núm. 1, pp. 143-151
-
Dendritic Cells in Cancer Immunology and Immunotherapy
Cancers, Vol. 16, Núm. 5
-
Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C
Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 4
-
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors
Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 3
-
Improving the Access of Highly Sensitized Patients to Kidney Transplantation From Deceased Donors: The Spanish PATHI Program With Allocation Based on the Virtual Crossmatch
Transplantation, Vol. 108, Núm. 3, pp. 787-801
-
Incidence of Diabetes Mellitus and Associated Factors in the Era of Antiretroviral Drugs With a Low Metabolic Toxicity Profile
Open Forum Infectious Diseases, Vol. 11, Núm. 4
-
Intratumoral NK cell delivery combined with neutralization of the NKG2A pathway as treatment for solid cancer
Genes and Immunity
-
Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040
Annals of Oncology, Vol. 35, Núm. 4, pp. 381-391
-
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040
Annals of Oncology, Vol. 35, Núm. 6, pp. 537-548
-
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
Clinical Cancer Research, Vol. 30, Núm. 8, pp. 1630-1641
-
Prevalence and Phenotypic Susceptibility to Doravirine of the HIV-1 Reverse Transcriptase V106I Polymorphism in B and Non-B Subtypes
Journal of Infectious Diseases, Vol. 229, Núm. 6, pp. 1796-1802
-
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial
Nature Communications, Vol. 15, Núm. 1
-
Serum mass spectrometry for treatment monitoring in patients with multiple myeloma receiving ARI0002h CAR T-cells
British Journal of Haematology
-
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease
Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 4
-
Spatially resolved tissue imaging to analyze the tumor immune microenvironment: beyond cell-type densities
Journal for immunotherapy of cancer, Vol. 12, Núm. 5
-
The liver as a cytokine factory working on mRNA blueprints for cancer immunotherapy
Cancer Cell
-
Tumor slice culture system for ex vivo immunotherapy studies
Methods in Cell Biology (Academic Press Inc.)